Alcobra Ltd. (Nasdaq:ADHD) announced the pricing of its previously announced underwritten public offering of 6,500,000 ordinary shares at an offering price of $4 …
In a research report sent to investors yesterday, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Alcobra Ltd (NASDAQ:ADHD), but reduced …
In a research report issued today, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Alcobra (NASDAQ:ADHD) with a $40 price target. The report comes …
In a research report issued today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Alcobra Ltd (NASDAQ:ADHD) with a price target of $40.00, …
In a research report issued today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Alcobra Ltd (NASDAQ:ADHD) with a price target …
In a research report published today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Alcobra Pharma (NASDAQ:ADHD), following first patient enrollment in a phase IIb study on …
In a research report published this morning, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Alcobra Pharma (NASDAQ:ADHD) with a $40 price target …
In a research note published today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Alcobra Pharma (ADHD) with a $40 price target, as the company commenced patient …
In a research note published yesterday, Canaccord Genuity analyst John Newman reaffirmed a Buy rating on Alcobra (ADHD), and a $40 price target, …
